Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company is headquartered in Gaithersburg, Maryland and currently employs 952 full-time employees. The firm offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. The company has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The firm is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Follow-Up Questions
Who is the CEO of Novavax Inc?
Mr. John Jacobs is the President of Novavax Inc, joining the firm since 2023.
What is the price performance of NVAX stock?
The current price of NVAX is $7.46, it has decreased 0.54% in the last trading day.
What are the primary business themes or industries for Novavax Inc?
Novavax Inc belongs to Biotechnology industry and the sector is Health Care
What is Novavax Inc market cap?
Novavax Inc's current market cap is $1.2B
Is Novavax Inc a buy, sell, or hold?
According to wall street analysts, 11 analysts have made analyst ratings for Novavax Inc, including 4 strong buy, 5 buy, 2 hold, 2 sell, and 4 strong sell
